Journal article
Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.
- Abstract:
- Acute lymphoblastic leukaemia/lymphoma is a malignant disorder derived from the clonal proliferation of lymphoid precursor cells. Whether the tumour cells are of B- or T-cell type is an important criterion for prognosis which has not been available previously to pathologists, due to the lack of a reliable early B-cell marker functioning on routinely processed material. This has changed with the production of monoclonal antibodies against the B-cell signalling molecule CD79a. CD79a is expressed on normal and neoplastic B cells from the early stages of B-cell maturation and has been considered to be B-cell-specific. Currently available antibodies against CD79a, in particular JCB117, allow the identification of B cells, and hence B lymphoblastic disease, in paraffin-embedded material. In this study, the expression of CD79a (JCB117) and CD3 has been investigated in 149 cases of T and 68 cases of B lymphoblastic leukaemia/lymphoma. For the first time, co-expression of CD79a (JCB117) and CD3 is reported in 10 per cent of cases of T lymphoblastic leukaemia/lymphoma. This finding raises questions about the co-expression of T- and B-cell markers in the development of lymphocytes, benign as well as malignant, and alerts pathologists to a potential problem in diagnosis.
- Publication status:
- Published
Actions
Access Document
Authors
- Journal:
- Journal of pathology More from this journal
- Volume:
- 186
- Issue:
- 2
- Pages:
- 140-143
- Publication date:
- 1998-10-01
- DOI:
- EISSN:
-
1096-9896
- ISSN:
-
0022-3417
- Language:
-
English
- Keywords:
-
- Pubs id:
-
pubs:486709
- UUID:
-
uuid:0c9d7766-70fe-4f59-a8a0-022aee73cd2b
- Local pid:
-
pubs:486709
- Source identifiers:
-
486709
- Deposit date:
-
2014-10-23
- ARK identifier:
Terms of use
- Copyright date:
- 1998
If you are the owner of this record, you can report an update to it here: Report update to this record